Axovant Sciences Ltd. (AXON) Takes Another Leg Lower

Yesterday's hot IPO for Axovant Sciences Ltd. (NYSE: AXON) took another leg lower mid-day. Shares are now down 18.3%.

As noted yesterday, scrutiny is surrounding the company given that its only product is an abandoned GlaxoSmithKline Alzheimer drug it bought for a mere $5 million. The market cap of the company is around $2B.

You May Also Be Interested In

• The West Can't Process Enough of This Critical Metal, and the Gap Doesn't Close by 2030
• Karman Line Acquisition closes $200M IPO on Nasdaq
• U.S. total public debt passes $40 trillion